Finance

Lists
Why is NTLA down ४.८४%?
Dive Deeper
NTLA:NASDAQ
Intellia Therapeutics Inc
US$ ११.९९
-४.८४%
(-०.६१) 1D
अक्टोबर ९, ०९:३९:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTLA...
Open
US$ १२.३६
High
US$ १२.४८
Low
US$ ११.९४
Mkt. cap
१.६८ अरब
Avg. vol.
४७.५३ लाख
Volume
१.४३ लाख
52-wk high
US$ २८.२४
52-wk low
US$ ७.९५
EPS
-US$ ३.३६
Beta
१.८०
Shares outstanding
१४.०१ करोड
No. of employees
३७७
Open
US$ १२.३६
High
US$ १२.४८
Low
US$ ११.९४
Mkt. cap
१.६८ अरब
Avg. vol.
४७.५३ लाख
Volume
१.४३ लाख
52-wk high
US$ २८.२४
52-wk low
US$ ७.९५
EPS
-US$ ३.३६
Beta
१.८०
Shares outstanding
१४.०१ करोड
No. of employees
३७७
News stories
From web sources and news partners
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees३७७
Founded२०१४
Headquartersक्याम्ब्रिज, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websiteintelliatx.com
Analyst ratings
Based on 14 analysts giving stock ratings to NTLA in the past 3 months
Hold
Buy
6
Hold
5
Sell
3
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for NTLA in the last 3 months.
Highest
Current US$ ११.९९
US$ ४९.०० (+३०८.६७%)
Average
US$ १९.०० (+५८.४७%)
Lowest
US$ ८.०० (-३३.२८%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eliana Merle
Barclays
Sell
Initiated
US$ ८.००
-३३.३%
10/07/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
US$ १५.००
+२५.१%
10/02/2026
David Nierengarten
Wedbush
Hold
Maintained
US$ १३.००
+८.४%
09/09/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
US$ २५.००
+१०८.५%
09/09/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
09/04/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
US$ २९.००
+१४१.९%
08/14/2026
Terence Flynn
Morgan Stanley
Hold
Reiterated
US$ १५.००
+२५.१%
08/10/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
US$ ४९.००
+३०८.७%
08/06/2026
Salveen Richter
Goldman Sachs
Sell
Maintained
US$ ९.००
-२४.९%
08/06/2026
Jonathan Miller
Evercore ISI
Buy
Upgraded
US$ २४.००
+१००.२%
08/07/2026
Luca Issi
RBC Capital
Hold
Maintained
US$ १५.००
+२५.१%
08/06/2026
Alec Stranahan
Bank of America Securities
Hold
Reiterated
US$ १७.००
+४१.८%
08/07/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/06/2026
Andy Chen
Wolfe Research
Sell
Downgraded
US$ ९.००
-२४.९%
07/15/2026
Unknown Analyst
Wedbush
Hold
Maintained
US$ १७.००
+४१.८%
07/10/2026
Brian Cheng
J.P. Morgan
Sell
Maintained
US$ ८.००
-३३.३%
05/13/2026
William Pickering
Bernstein
Hold
Reiterated
US$ १७.००
+४१.८%
05/13/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
US$ १५.००
+२५.१%
05/12/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
US$ ३०.००
+१५०.२%
04/28/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
US$ ३०.००
+१५०.२%
04/27/2026
Mani Foroohar
Leerink Partners
Buy
Reiterated
US$ ३५.००
+१९१.९%
04/27/2026
Jack Allen
Robert W. Baird
Hold
Maintained
US$ १३.००
+८.४%
04/27/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१.३८ करोड
२.३० करोड
१.५० करोड
७६.५९ लाख
Cost of goods sold
७.८९ करोड
७.३६ करोड
८.०७ करोड
८.२६ करोड
Cost of revenue
७.८९ करोड
७.३६ करोड
८.०७ करोड
८.२६ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
४.६३ करोड
४.८१ करोड
३.४८ करोड
३.७८ करोड
Operating expense
४.६३ करोड
४.८१ करोड
३.४८ करोड
३.७८ करोड
Total operating expenses
१२.५३ करोड
१२.१७ करोड
११.५६ करोड
१२.०४ करोड
Operating income
-११.१५ करोड
-९.८७ करोड
-१०.०५ करोड
-११.२८ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-१०.१३ करोड
-९.५८ करोड
-९.६२ करोड
-१०.६६ करोड
EBT excluding unusual items
-१०.४८ करोड
-९.२२ करोड
-९.५३ करोड
-१०.७० करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१०.१३ करोड
-९.५८ करोड
-९.६२ करोड
-१०.६६ करोड
Net profit margin
-७३५.१९%
-४१६.१५%
-६३९.४९%
-१,३९२.२७%
Earnings per share
-०.९२
-०.८३
-०.८१
-०.८०
Interest and investment income
६७.१४ लाख
६४.७६ लाख
५२.०५ लाख
५७.९७ लाख
Interest expense
-
-
-
-
Net interest expenses
६७.१४ लाख
६४.७६ लाख
५२.०५ लाख
५७.९७ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१०.९१ करोड
-९.६३ करोड
-९.८३ करोड
-११.०७ करोड
Gain or loss from assets sale
-
५.२७ लाख
-
१.५३ लाख
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू